No Data
"Flourish in Color • She Blooms" 2025 Breast Cancer Care Charity Event was successfully held, creating a benchmark brand for psychological care of breast cancer patients in China.
Shanghai, March 30, 2025 /PR Newswire/ -- On March 29, 2025, the "Colorful in Pink • She Blossoms" breast cancer care public welfare event, jointly organized by the Shanghai Fosun Public Welfare Fund, Guangdong Daily Media Group, and the Guangdong Life Light Cancer Rehabilitation Association, with strong support from HENLIUS, was successfully held in Guangzhou. The event gathered over 100 guests, including medical experts, public welfare organizations, media representatives, enterprise representatives, and breast cancer patients, focusing on the mental health and social support of breast cancer patients. During the event, the "Initiative for Mental Health and Social Care for Breast Cancer Patients" was released, aimed at uniting society.
Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug
Shanghai Henlius Biotech's HLX11 Biosimilar Gains EMA Validation
HENLIUS (02696): The marketing authorization application (MAA) for the biosimilar of patzuumab HLX11 (anti-HER2 domain II humanized monoclonal antibody injection) has been accepted by the European Medicines Agency (EMA).
HENLIUS (02696) announced that recently, the company's independently developed Perjeta (pertuzumab)...
Express News | Shanghai Henlius Biotech Inc - Marketing Authorization Application ( for Pertuzumab Biosimilar Hlx11 Validated by European Medicines Agency
Shanghai Henlius Advances Phase 3 Trial of HLX22 in Japan
